Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 8,939 |
|
|||||
| News | - | ||||||
| Day High | 5.58 | Low High |
|||||
| Day Low | 5.3297 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| CalciMedica Inc | CALC | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.16 | 3.02% | 5.45 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 5.50 | 5.3297 | 5.58 | 5.45 | 5.29 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 135 | 8,939 | US$ 5.48 | US$ 48,959 | - | 1.75 - 8.59 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:00:00 | 151 | US$ 5.45 | USD |
CalciMedica Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 30.41M | 5.68M | - | 0 | -34.36M | -6.04 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
CalciMedica News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CALC Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.01 | 5.80 | 4.01 | 5.25 | 24,319 | 1.44 | 35.91% |
| 1 Month | 4.01 | 5.80 | 3.88 | 4.59 | 20,489 | 1.44 | 35.91% |
| 3 Months | 6.25 | 6.56 | 3.3101 | 4.46 | 21,161 | -0.80 | -12.80% |
| 6 Months | 2.06 | 8.38 | 1.81 | 4.31 | 19,023 | 3.39 | 164.56% |
| 1 Year | 4.70 | 8.59 | 1.75 | 3.92 | 18,679 | 0.75 | 15.96% |
| 3 Years | 5.27 | 8.59 | 1.75 | 4.06 | 19,550 | 0.18 | 3.42% |
| 5 Years | 5.27 | 8.59 | 1.75 | 4.06 | 19,550 | 0.18 | 3.42% |
CalciMedica Description
| CalciMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for life-threatening inflammatory diseases with high unmet needs. Its technology targets the inhibition of Calcium Release-Activated Calcium (CRAC) channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases. CRAC channels serve to replenish calcium levels in the endoplasmic reticulum (ER) and provide calcium for cellular signaling events. Its lead product candidate, Auxora, is an intravenous-formulated, small molecule CRAC channel inhibitor. Auxora has the capability to modulate the immune response and protect against tissue cell injury, addressing inflammatory diseases, such as acute pancreatitis (AP), asparaginase-associated acute pancreatitis (AAP), acute kidney injury (AKI), and acute hypoxemic respiratory failure. |
